Overview
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
Status:
Completed
Completed
Trial end date:
2015-04-01
2015-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Capecitabine
Oxaliplatin
Criteria
Inclusion Criteria:- Adult participants, >/= 18 years of age
- Treatment in line with the currently approved indication in the Summary of Product
Characteristics
Exclusion Criteria:
- Contraindications according to the current Summary of Product Characteristics